Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes.


Journal

Pathobiology : journal of immunopathology, molecular and cellular biology
ISSN: 1423-0291
Titre abrégé: Pathobiology
Pays: Switzerland
ID NLM: 9007504

Informations de publication

Date de publication:
2019
Historique:
received: 16 01 2018
accepted: 08 06 2018
pubmed: 19 9 2018
medline: 23 1 2019
entrez: 19 9 2018
Statut: ppublish

Résumé

Myelodysplastic syndromes (MDS) are a challenging group of diseases for clinicians and researchers, as both disease course and pathobiology are highly heterogeneous. In (suspected) MDS patients, multi-parameter flow cytometry can aid in establishing diagnosis, risk stratification and choice of therapy. This review addresses the developments and future directions of multi-parameter flow cytometry scores in MDS. Additionally, we propose an integrated diagnostic algorithm for suspected MDS.

Identifiants

pubmed: 30227408
pii: 000490727
doi: 10.1159/000490727
pmc: PMC6482988
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-23

Informations de copyright

© 2018 The Author(s) Published by S. Karger AG, Basel.

Références

Blood. 2001 Aug 15;98(4):979-87
pubmed: 11493442
Blood. 2002 Dec 1;100(12):3887-96
pubmed: 12393641
Leuk Lymphoma. 2002 Oct;43(10):1927-31
pubmed: 12481886
Blood. 2003 Jul 1;102(1):394-403
pubmed: 12649150
Blood. 2005 Nov 1;106(9):2982-91
pubmed: 16076868
Ann Hematol. 2008 Jul;87(7):515-26
pubmed: 18414863
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
Eur J Clin Invest. 2009 Jul;39(7):548-53
pubmed: 19453651
Haematologica. 2009 Aug;94(8):1124-34
pubmed: 19546437
Haematologica. 2009 Aug;94(8):1066-74
pubmed: 19546439
Blood. 2010 Mar 4;115(9):1779-84
pubmed: 20038788
Leuk Res. 2011 Jul;35(7):868-73
pubmed: 21397943
Am J Clin Pathol. 2012 Jan;137(1):75-85
pubmed: 22180480
Haematologica. 2012 Jun;97(6):895-902
pubmed: 22271903
Leukemia. 2012 Jul;26(7):1730-41
pubmed: 22307178
Haematologica. 2012 Aug;97(8):1209-17
pubmed: 22315489
Leukemia. 2012 Sep;26(9):1908-75
pubmed: 22552007
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Haematologica. 2013 Feb;98(2):201-7
pubmed: 22929975
Leuk Res. 2013 Mar;37(3):266-73
pubmed: 23153526
Nat Methods. 2013 Mar;10(3):228-38
pubmed: 23396282
Cytometry B Clin Cytom. 2013 May;84(3):157-66
pubmed: 23475532
Leukemia. 2013 Oct;27(10):1981-7
pubmed: 23765225
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Int J Lab Hematol. 2014 Apr;36(2):184-96
pubmed: 24118926
Haematologica. 2014 Jan;99(1):e8-10
pubmed: 24425693
Cytometry B Clin Cytom. 2014 May;86(3):207-15
pubmed: 24474614
Haematologica. 2015 Mar;100(3):e93-6
pubmed: 25425689
Haematologica. 2015 Apr;100(4):472-8
pubmed: 25637056
Blood. 2015 Jun 4;125(23):3618-26
pubmed: 25852055
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582
Int J Lab Hematol. 2015 May;37 Suppl 1:133-43
pubmed: 25976971
Ann Hematol Oncol. 2015;2(5):null
pubmed: 26203464
Blood. 2015 Nov 19;126(21):2355-61
pubmed: 26429975
Cytometry A. 2016 Jan;89(1):16-21
pubmed: 26447924
Leukemia. 2016 Mar;30(3):658-65
pubmed: 26503643
Cytometry B Clin Cytom. 2016 Jul;90(4):358-67
pubmed: 26517178
Eur J Cancer. 2016 Feb;54:49-56
pubmed: 26720403
Oncoimmunology. 2015 Jun 24;5(2):e1062208
pubmed: 27057428
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Nat Rev Immunol. 2016 Jul;16(7):449-62
pubmed: 27320317
IEEE Trans Biomed Eng. 2017 May;64(5):1089-1098
pubmed: 27416585
Front Oncol. 2016 Jul 20;6:172
pubmed: 27489795
Haematologica. 2017 Feb;102(2):320-326
pubmed: 27658438
Oncotarget. 2016 Nov 1;7(44):71915-71921
pubmed: 27713120
Haematologica. 2017 Feb;102(2):308-319
pubmed: 27758818
Leuk Res. 2017 May;56:1-6
pubmed: 28152413
Blood. 2017 Mar 30;129(13):1881-1883
pubmed: 28159734
Cytometry B Clin Cytom. 2018 Mar;94(2):219-229
pubmed: 28257592
Blood. 2017 Aug 10;130(6):832-835
pubmed: 28611023
J Leukoc Biol. 2017 Oct;102(4):1055-1068
pubmed: 28720687
Cytometry B Clin Cytom. 2018 May;94(3):484-492
pubmed: 28865180
Lancet Oncol. 2017 Oct;18(10):1338-1347
pubmed: 28870615
Haematologica. 2017 Dec;102(12):2058-2068
pubmed: 28883080
Semin Hematol. 2017 Jul;54(3):159-166
pubmed: 28958290
Oncotarget. 2017 Jul 5;8(43):73483-73500
pubmed: 29088721
Oncotarget. 2017 Jul 27;8(47):82475-82490
pubmed: 29137279
Exp Hematol. 2018 Feb;58:17-26
pubmed: 29175473
J Immunol. 2018 Jan 15;200(2):422-431
pubmed: 29311384

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH